Abstract: Compounds of formula I ##STR1## where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, n, and are as defined herein, their use as antiinflammatory, immunosuppressive, and antiallergic agents, pharmaceutical compositions comprising them, and methods for their preparation comprising irradiating compounds of formula II ##STR2## under an inert atmosphere, in the presence or absence of a compound of formula R.sub.3 --S--S(O).sub.m --R.sub.8, where R.sub.7, R.sub.8, and m are as defined herein, and methods for their preparation comprising oxidizing, reducing, halogenating, or alkylating compounds of formula I are disclosed.

Abstract: A second-step virus binding receptor is found in nature on the surface of animal and plant cells. This receptor is thought to be needed for virus penetration into target cells. The second-step receptor has been found to bind a wide variety of viruses belonging to a number of different families. The second-step receptor and natural or synthetic substances which correspond to or are analogous to the binding epitope of the second-step receptor in that they are able to bind to a site on the virus which recognizes the binding epitope of the natural second-step receptor, are therefore indicated for the diagnosis, prophylaxis or treatment of viral infections.

Abstract: A second-step virus binding receptor is found in nature on the surface of animal and plant cells. This receptor is thought to be needed for virus penetration into target cells. The second-step receptor has been found to bind a wide variety of viruses belonging to a number of different families. The second-step receptor and natural or synthetic substances which correspond to or are analogous to the binding epitope of the second-step receptor in that they are able to bind to a site on the virus which recognizes the binding epitope of the natural second-step receptor, are therefore indicated for the diagnosis, prophylaxis or treatment of viral infections.

Abstract: A composition for therapeutic or diagnostic use in connection with the toxine of Shigella dysenteriae. As an active constituent the composition contains or consists of a compound having the formula (I): ##STR1## wherein R.sub.1 is hydrogen or an organic residue, and R.sub.2 is hydrogen, alkyl, alkoxi or a carbohydric residue with the proviso that R.sub.2 is not .beta.-D-GalNacp-(1-0) when R.sub.1 is D-Glc or -.beta.-D-Glcp-(1-0)-ceramide and that R.sub.2 is different from OH,.alpha.-D-GalNAcp-(1-3)-.beta.-D-GalNAcp-(1-0)-,.beta.-D-GalNAcp-(1-3)-.beta.-D-GalNAcp-(-0)-,.alpha.-L-Fucp-(1-2)-.beta.-D-Galp-(1-3)-.beta.-D-GalNAcp-(1-0)- and.alpha.-L-Fucp-(1-2)-.alpha.-D-Galp-(1-3)-(1-0)-;a method for therapeutic treatment; and the use of the composition for therapeutic treatment or diagnosis.

Abstract: Monoclonal antibodies recognizing the difucosyl-type-2-H antigen on human cells and a method of producing said antibodies are disclosed. The monoclonal antibodies are useful in blood typing and in diagnosis of blood disorders and malignancies involving loss or gain of this H antigen.

Abstract: A method for phase-locked sampling measurement of a periodically varying quantity. The samples are designated g(I) . . . g(I-n) and may comprise one complete period or a half of one period. The method involves adapting the sampling frequency and the sample position in relation to the quantity to be measured such that phase locking is attained, and this is done by controlling the time interval between sampling. Whether the sampling frequency needs to be increased, left unchanged or be decreased, depends on a number of decisions depending on the values of samples g(I) and g(I)-g(I-n). A device for carrying out the method is also described.